drugset

drugset / Trial / NCT00964132

Oral NRX 194204 Study in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00964132 ↗

Phase 2 Unknown 48 enrolled NuRx Pharmaceuticals, Inc.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether NRX 194204 is effective in the treatment of advanced Non-Small Cell Lung Cancer (NSCLC).

Timeline

Start: 2009-03
Primary completion: 2010-03
Completion: 2010-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	IRX4204	Small molecule	—	Oral

Indications